[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633473":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":36,"responsibleParty":54,"collaborators":10,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":10,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":10,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Participants complete a semi-structured interview on study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Non-Interventional Study","Non-interventional study",[9],[20,21],"Non-Interventional Observational Study","Noninterventional (Observational) Study",[23],{"name":24,"affiliation":25,"role":26},"Shariska Harrington, MD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":10},"Kelly Gunderson","507-422-1892",[37],{"facility":25,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-92.4699,44.02163,{"lat":48,"lon":47},[51,52,53],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":10},{"name":34,"role":30,"phone":35,"phoneExt":10,"email":10},{"name":24,"role":26,"phone":10,"phoneExt":10,"email":10},{"type":26,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Shariska Harrington","Principal Investigator","100633473","acceptability-of-testing-dna-markers-in-vaginal-fluid-for-the-detection-of-endometrial-cancer-100633473",false,"NCT07527143","Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer","Inclusion Criteria:\n\n* Self-identified Black individuals ≥ 45 years with an intact uterus\n* Assigned female sex at birth\n* Experience with abnormal uterine or post-menopausal bleeding (defined as vaginal bleeding between periods, heavy vaginal bleeding, vaginal bleeding after menopause, and\u002For red, brown, or pink colored vaginal discharge after menopause)\n* Willing to participate in a 45-minute virtual interview\n\nExclusion Criteria:\n\n* Previous or current diagnosis of endometrial cancer",true,"FEMALE","45 Years",{"count":67,"type":68},25,"ESTIMATED","OBSERVATIONAL","This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.",[72],"Endometrial Carcinoma","2026-07-07",{"date":75,"type":76},"2026-07-09","ACTUAL",{"date":78,"type":76},"2026-06-10",{"date":80,"type":68},"2027-06-10",{"name":5,"class":6},1]